Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 601–700 of 786
Prediction and treatment of bleeding in patients under anticoagulant treatment
Páramo, J. A. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.06.031 · Cited by 2
Venous Thromboembolism for the Practicing Cardiologist
Pribish, A. M., Secemsky, E. A., & Schmaier, A. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.06.008 · Cited by 1
Cancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors
Grilusová, K., Bolek, T., Škorňová, I., Staško, J., Samoš, M., & Mokáň, M. (2021) · Klinicka onkologie · doi:10.48095/ccko2021283 · Cited by 1
Update: Antikoagulationstherapie bei tumorassoziierter venöser Thromboembolie
Riess, H. B. (2022) · Aktuelle Kardiologie · doi:10.1055/a-1693-2412 · Cited by 1
Role of Follow-Up Duplex Ultrasound Post-Deep Vein Thrombosis
Broering, M. J., & Muck, P. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-60626-8_67 · Cited by 1
Pulmonary Thromboembolism and COVID-19: Place for Anticoagulant Therapy
Trisvetova, E. L. (2020) · Кардиология в Беларуси · doi:10.34883/pi.2020.12.3.007 · Cited by 1
Held, M., Joa, F., & Wilkens, H. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-0010-6 · Cited by 2
Ramallo, H. R., Gutiérrez, N. B., Martín, L. A., & Otero, R. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.09.023 · Cited by 2
Schürch, K. A., Holy, E. W., Kucher, N., & Barco, S. (2022) · Praxis · doi:10.1024/1661-8157/a003949 · Cited by 1
Gary, T. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_11 · Cited by 1
Unapproved Dose of Direct Oral Anticoagulants for Venous Thromboembolism ― Right or Wrong? ―
Adachi, S., Adachi, T., & Nakano, Y. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0063 · Cited by 1
Duration of anticoagulation for unprovoked venous thromboembolism
Kimpton, M., & Wang, T. (2025) · BMJ · doi:10.1136/bmj.r2334 · Cited by 1
Verlängerte VTE-Prophylaxe: Rivaroxaban deutlich besser als ASS
Overbeck, P. (2017) · CardioVasc · doi:10.1007/s15027-017-1099-8
Risk of recurrence lower with rivaroxaban than aspirin
Huynh, K. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.41
Rivaroxaban ist wirksamer als Aspirin bei Verhinderung erneuter venöser Thromboembolien
Steurer, J. (2017) · Praxis · doi:10.1024/1661-8157/a002714
Current Tendencies in the Prevention of Recurrent Venous Thromboembolism
Ilyukhin, Е. А., & Zolotukhin, I. A. (2017) · Journal of Venous Disorders · doi:10.17116/flebo201711283-90 · Cited by 1
Tiefe Venenthrombose: Wie lang antikoagulieren?
Schumacher, B. (2017) · CME · doi:10.1007/s11298-017-6292-7
Palareti, G. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1366851
Long-term strategies in patients with unprovoked venous thromboembolism
Prandoni, P. (2017) · Phlebologie · doi:10.12687/phleb2372-5-2017
Self-citationKaretová, D., & Bultas, J. (2017) · Klinická farmakologie a farmacie · doi:10.36290/far.2017.014
Update On the Use of Direct Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Jacobs, A. R., Kabra, R., Das, P., & Oliphant, C. S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0045
Thrombose, Lungenembolie und Antikoagulation: Wie und wie lange antikoagulieren?
Geisler, T., & Stimpfle, F. (2018) · Der Klinikarzt · doi:10.1055/a-0575-1650
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism
Nakai, Y., Sumise, Y., Yamaguchi, T., & Okamoto, H. (2018) · The Japanese Journal of Phlebology · doi:10.7134/phlebol.17-24
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Anticoagulation in Venous Thromboembolism
Barnes, G. D., & Renner, E. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_14
Closing Patent Foramen Ovale (PFO) for Cryptogenic Stroke - Deeper Thoughts
Wong, C. K. (2018) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000e139
Transitioning Between Anticoagulants
Serhal, M., & Gomes, M. P. V.-F. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_7
Quelle durée de traitement après un événement thromboembolique veineux ?
Couturaud, F., & Mahé, I. (2018) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.03.383
Romero, J. M. C., & Rodríguez, E. M. L. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2018.05.004 · Cited by 1
ACC highlights promising studies
Tanzi, M. G. (2017) · Pharmacy Today · doi:10.1016/j.ptdy.2017.05.033
Vanassche, T., & de Werf, F. V. (2018) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2018.09.015
Cho, J. H., & Kim, Y. (2018) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.18001
EINSTEIN-CHOICE trial – rationale for the extended anticoagulation in secondary prevention
Tamburrini, L. R., Weißer, G., & Espinola–Klein, C. (2018) · VASA · doi:10.1024/0301-1526/a000707
Maladie thromboembolique veineuse chez le sujet âgé
Delrue, M., Pautas, É., & Siguret, V. (2019)
EXTENDED ANTICOAGULANT THERAPYIN PATIENTS, WHO SURVIVED PULMONARY EMBOLISM
Vorobieva, N. M., & Панченко, Е. П. (2018) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2018-2-36-45
8. Jahrestagung der Vereinigung der interdisziplinären Gefäßmediziner Süddeutschlands (VIGS)
Storck, M., Amendt, K., & Grundmann, R. T. (2019) · Gefässchirurgie · doi:10.1007/s00772-019-0512-2
Валерьевич, А. О., Vechorko, V. I., & Shapsigova, O. A. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-21-8-15
Chan, N., & Weitz, J. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00059-x · Cited by 1
Self-citationEpidemiology of venous thromboembolism with focus on risk markers
Johansson, M. (2019) · DiVA at Umeå University (Umeå University)
Use of Rivaroxaban in Patients Attending a Hematology Unit in Clinical Practice
Gavín‐Sebastián, O., Izuzquiza, M., Fernández, R. M., & Bernal, L. P. (2019) · Future Cardiology · doi:10.2217/fca-2018-0086
Moayyedi, P., Eikelboom, J. W., & Yusuf, S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.10.032
Oxidative Stress as a Thrombophilic Factor in Behçet Syndrome
Emmi, G., Becatti, M., Bettiol, A., Fiorillo, C., & Prisco, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-24131-5_14 · Cited by 1
Recirculation syndrome in hemodialysis patients
Kalinin, R. E., Suchkov, I. A., Egorov, A. A., & Klimentova, E. A. (2019) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia201911124
RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM
Erlikh, A. D. (2020) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2019-2-10-18
Storck, M., Huppert, P., Amendt, K., & Grundmann, R. T. (2020) · Gefässchirurgie · doi:10.1007/s00772-020-00630-7
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J., Müller, O.-A., Pfeifer, M. A., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50012-7
Methods of Venous Thromboembolic Prophylaxis in Orthopedic Surgeries
Khalil, S. A., Rizk, A., Elsheikh, A. A., & Ragheb, B. (2020) · Benha Medical Journal · doi:10.21608/bmfj.2020.113208
Utilize the full potential of real world evidence
Bauersachs, R. M. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.10.008
Self-citationInnovation and standardization of near-patient platelet function assays
Sang, Y. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20201111ys
Xi, Z., Gong, X., Li, B., Zhang, L., Pu, J. Y., Li, Y., Xu, Y., & Zhang, M. (2020) · PubMed Central · doi:10.7507/1001-5515.202008001 · Cited by 1
Updates on the use of direct oral anticoagulants for the management of chronic conditions
Gibson, C. M. (2020) · Pharmacy Today · doi:10.1016/j.ptdy.2020.11.019
Extended therapy and secondary prevention of venous thromboembolic complications
Petrikov, A. S., & Игоревич, П. И. (2020) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj2020284548-566
Thrombosis with Thrombocytopenia - A Vascular Paradox
Nanjappa, V., Devegowda, L., Rathore, A., Sadanand, K. S., & Nanjappa, M. C. (2020) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2020/634
Instal·lacions tèrmiques d'un poliesportiu
de la Fuente, X. P. (2010) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Risque de maladie thromboembolique veineuse dans la polyarthrite rhumatoïde
Ketfi, C., Boutigny, A., Mohamedi, N., Bouajila, S., Magnan, B., Amah, G., & Dillinger, J. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.05.006 · Cited by 2
Infrarenal inferior vena cava agenesis
Fajardo, G. P., & Leon, M. P. (2021) · Medical Research Archives · doi:10.18103/mra.v9i5.2389
Anantharaju, G. S., Basavarajappa, M., Vikram, S., & Ravishankar, Y. R. (2021) · International Surgery Journal · doi:10.18203/2349-2902.isj20212329
Clinical Indications for Direct Acting Oral Anticoagulants
AlTurki, A., & Proietti, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-74462-5_2
Role of Follow-Up Duplex Ultrasound Post-Deep Vein Thrombosis
Broering, M. J., & Muck, P. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-49616-6_67-1
Qual droga utilizar para o tratamento prolongado de tromboembolismo venoso?
Bendine, A. Z., & Costa, J. A. (2021) · Revista da Faculdade de Ciências Médicas de Sorocaba · doi:10.23925/1984-4840.2020v22i2a9
The Effect of Anticoagulant in Patients with Cirrhosis Associated with Acute Portal Vein Thrombosis
Jo, H. G., Kim, Y. R., & Cho, E. Y. (2021) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.050
Can I Stop Anticoagulation When Cancer Is in Remission?
Koitabashi, N. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0881
Arendt, V. A., & Hofmann, L. V. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2021.11.012
Postigo, A., Mombiela, T., Bermejo, J., & Fernández‐Avilés, F. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.011
Pulmonary Embolism and Deep Vein Thrombosis
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch21
Review of the British Thoracic Society Winter Meeting 2017, 6–8 December 2017, London, UK
Singanayagam, A., Woodcock, H. V., Molyneaux, P. L., & Jenkins, G. R. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-212012
Difficult Choice: When to Prolong Anticoagulation Therapy in Patients with Venous Thromboembolism?
Хрыщанович, В. Я., & Скобелева, Н. Я. (2021) · Кардиология в Беларуси · doi:10.34883/pi.2021.13.5.016
MacKellar, R. (2021) · journal australiasian society aerospace medicine · doi:10.21307/asam-2020-005
Chang, C.-L., Lin, Y.-J., Pan, C.-C., & Kuo, C.-N. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221084418
Pathway for the Diagnosis and Management of Pulmonary Embolism
Herzog, E., Elbaz‐Greener, G., Planer, D., Koren, T., Amir, O., Shapiro, J. M., & Kalish, Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-87090-4_1
Direct oral anticoagulant drugs in the treatment of pulmonary thromboembolism
Obradovic, S. D., Džudović, B., Šalinger-Martinović, S., Matijašević, J., & Kovacevic, T. (2022) · Galenika Medical Journal · doi:10.5937/galmed2201015o
Extended Anticoagulation in Cancer-associated Thrombosis (CAT): Can We Lower the Dose Yet?
Scott, J., & Tseng, E. K. (2022) · The Hematologist · doi:10.1182/hem.v19.3.202234
Venous thromboembolism in Portuguese hospitals: Where we stand and how we can improve
Castro, G. (2017) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2017.11.002
5) Deep Vein Thrombosis and Pulmonary Thromboembolism: Current Strategy of Antithrombotic Therapy
Yamada, N. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.1875
Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis
Evoy, K. E., Isch, J., & Raber, H. (2018) · Side effects of drugs annual · doi:10.1016/bs.seda.2018.06.012
Minvielle, F., & Jeune, S. L. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-77465-2.00009-6
Konstantinides, S., Kurzyna, M., & Torbicki, A. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849346.003.0064
Scientific Surgery June 2017 BJS
(2017) · British journal of surgery · doi:10.1002/bjs.10591
4 Clinical applications of aspirin
Schrör, K. (2022) · De Gruyter eBooks · doi:10.1515/9783110746419-004
Hosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4147518
DOAC — not for everyone, and sometimes at different dose
Musiał, J. (2022) · Journal of Transfusion Medicine · doi:10.5603/jtm.2022.0012
Galanaud, J. ‐. (2022) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2022.07.008
Simioni, P., Pengo, V., & Prandoni, P. (2022) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2022.52
Self-citationProtocolo de anticoagulación en la tromboembolia pulmonar
Durán, D., & Guerrero, R. M. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.11.017
Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis
Hamad, A. K. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.362812
Traitement anticoagulant de la maladie thromboembolique veineuse à la phase chronique
Élias, A., & Daoud-Elias, M. (2023) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2023.04.008
Extension Treatment: Preventing Recurrence of Venous Thromboembolism
SUTTON, D. R., & Rhodes, S. (2023) · EMJ Hematology · doi:10.33590/emjhematol/10306891
Risk Assessment and Duration of Therapy
Toolan, S., Edebiri, O., Áinle, F. N., & Kevane, B. (2023) · Springer eBooks · doi:10.1007/978-3-030-70904-4_38-1
Gerinnungsstörungen bei Tumorpatienten
Riess, H. B. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_313-1
Antikoagulation und Thrombozytenaggregationshemmung bei chronischer Nierenkrankheit
Heine, G. H. (2023) · Springer eBooks · doi:10.1007/978-3-662-65648-8_29
Rath, D. (2023) · Notfallmedizin up2date · doi:10.1055/a-1984-3290
Microcirculation - Updates in the Next Frontier of Vascular Disease
Kibel, A., & Firstenberg, M. S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001544
Souza, D. H. I., de Almeida, N. A., Domingues, M. L. D. P., Baldoni, A. O., Baldoni, N. R., & Rios, D. R. A. (2023) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2023.196548
Ertürk, E., Ocak, K., Uyan, U., Çoner, A., Kocabaş, U., Kış, M., Başkurt, A. A., Oray, D., Sayın, B. Y., Mammadov, G., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2688
Conde, I. D., & Madassery, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-36480-8_11
Oral anticoagulation therapy in the treatment of pulmonary thromboembolism
Omčikus, M., & Milivojević, I. (2023) · Galenika Medical Journal · doi:10.5937/galmed2305062o
Verlängerte medikamentöse Sekundärprophylaxe venöser Thromboembolien (VTEs)
Bauersachs, R. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_130-1
Self-citationAntiplatelet period drama: a rush of blood or classic crimson tide?
Martens, K. L., & Bannow, B. S. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102320
Pimentel-Esparza, J. A., Rios-Gomez, M., Cervantes-Nieto, J. A., & Mendoza, J. A. F. (2024) · Cureus · doi:10.7759/cureus.52985
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.